MedTrace Logo

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

NCT00348894 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2011-06-01

No results posted yet for this study

Summary

The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy

Conditions

Interventions

DRUG

[S,S]-Reboxetine

\[S,S\]-reboxetine

DRUG

Any

Any standard of care treatment for DPN

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States
  • Argentina
  • Canada
  • Croatia
  • Estonia
  • Finland
  • Germany
  • India
  • Poland
  • Russia
  • South Africa
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348894 on ClinicalTrials.gov